systematic review is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Although he rejected Felipe González's offer to form a broad-based parliamentary government, Calvo Sotelo agreed with the PSOE on the two most urgent issues, the "military question" and the "regional question". Regarding the former, the Socialists agreed that only 32 of the more than 200 military personnel involved in the coup would be tried and only one civilian ─ Tejero, Armada and Milans del Bosch were sentenced by the Supreme Court to the maximum penalty of thirty years in prison ─ and also supported the Law for the Defense of the Constitution aimed at preventing any new coup attempt. Regarding the "regional question", UCD and PSOE agreed on the Organic Law for the Harmonization of the Autonomous Process (in Spanish, Ley Orgánica de Armonización del Proceso Autonómico or LOAPA) aimed at "reordering" the so-called "Regional state". The government did not find the support of the PSOE in the decision to apply for Spanish membership in NATO and when it was approved in Congress on October 29, 1981, Felipe González promised that when he took power he would call a referendum on permanence.
Galectin-7 is a protein that in humans is encoded by the LGALS7 gene. The galectins are a family of beta-galactoside-binding lectins involved in modulating cell–cell and cell–matrix interactions. LGALS7 is specifically expressed in keratinocytes and at all stages of epidermal differentiation, including the basal and suprabasal layers. Expression is moderately repressed by retinoic acid. In tissue sections, galectin-7 localizes primarily to basal keratinocytes but is also found, at lower levels, in suprabasal layers where it concentrates at sites of cell–cell contact. Its down-regulation in cultured keratinocytes suggests a role in adhesion-related growth control. Galectin-7, like other galectins, binds carbohydrate structures containing galactose. Galactosides contribute to glycoprotein architecture and to processes such as oligosaccharide hydrolysis, and the structural diversity of these sugars underlies the selective affinity of galectins for their glycan ligands. Consistent with its keratinocyte-specific expression, galectin-7 is abundant in the epidermis and other stratified epithelia. The LGALS7 gene participates in fundamental cellular processes such as apoptosis and cell–cell interactions. Galectin-7 contributes to epithelial maintenance, wound repair, and cellular stress responses, and shows context-dependent roles in immunity, infection, and cancer. Its carbohydrate-binding specificity gives rise to distinct signaling outputs, making therapeutic targeting challenging.
The new constitution, proclaiming a democratic republic, direct universal suffrage, and the separation of powers, was promulgated on 4 November 1848. Under the new constitution, there was to be a single permanent Assembly of 750 members elected for a term of three years by the scrutin de liste. The Assembly would elect members of a Council of State to serve for six years. Laws would be proposed by the Council of State, to be voted on by the Assembly. The executive power was delegated to the president, who was elected for four years by direct universal suffrage, i.e. on a broader basis than that of the Assembly, and was not eligible for re-election. He was to choose his ministers, who, like him, would be responsible to the Assembly. Revision of this constitution was made practically impossible: it involved obtaining three times in succession a majority of three-quarters of the deputies in a special assembly. It was in vain that Jules Grévy—on behalf of those who perceived the obvious and inevitable risk of creating, under the name of a president, a monarch and indeed one who was more than a king at that—proposed that the head of the state should be no more than a removable president of the ministerial council. Lamartine, thinking that he was sure to be the choice of the electors under universal suffrage, won over the support of the Chamber, which did not even take the precaution of rendering ineligible the members of families which had reigned over France. It made the presidency an office dependent upon popular acclamation.
Sources: en.wikipedia.org
=== Buc–But === Eduard Buchner (1860–1917), German chemist who sounded the death knell of vitalism by discovering cell-free fermentation, 1907 Nobel Prize in Chemistry Stephen L. Buchwald (born 1955), American organic chemist, co-discoverer of palladium-catalyzed C–N bond formation Buchwald–Hartwig amination Mary Van Rensselaer Buell (1893–1969), American chemist who worked on nucleic acids and nucleotides, the relation of hormones to the metabolism of carbohydrates, and other topics in biochemistry Kathryn Bullock (1945–2021), American chemist who co-developed valve-regulated lead-acid batteries Robert Wilhelm Bunsen (1811–1899), German inventor, chemist, discovered the elements caesium and rubidium with Gustav Kirchhoff and invented the Bunsen burner Jeanne Burbank (1915–2002), American chemist who developed lead-acid and silver-zinc batteries for submarines at the United States Naval Research Laboratory Stephanie Burns (born 1955), American organosilicon chemist and past honorary president of Society of Chemical Industry William Merriam Burton (1865–1954), American chemist, developed the first thermal cracking process for crude oil Adolf Butenandt (1903–1995), German biochemist, 1939 Nobel Prize in Chemistry for "work on sex hormones" Alison Butler (PhD 1982), American bioinorganic chemist and metallobiochemist Aleksandr Butlerov (1828–1886), Russian chemist, one of the creators of the theory of chemical structure, who discovered the formose reaction
=== Physical properties === Adipose tissue has a density of ~0.9 g/ml. Thus, a person with more adipose tissue will float more easily than a person of the same weight with more muscular tissue, since muscular tissue has a density of 1.06 g/ml.
Because of its limited availability and high cost, the 1H-MRS technique cannot be proposed for all children whose clinical condition suggests the diagnosis of brain creatine depletion. AGAT deficiency is, along with GAMT and creatine transporter defect, one of three inborn errors of the creatine biosynthesis/transport pathway. The prevalence of these defects is unknown, however they have been observed to occur in high frequency in intellectually disabled children. The actual genetic mutation associated with AGAT involves a tryptophan codon being converted to a stop codon at residue 149.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.